NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) reported results today for the three months and year ended December 31, 2008. For the three months ended December 31, 2008, the company reported net income attributable to common stockholders of $5.1 million, or $0.08 per share, basic and diluted, compared with a net loss attributable to common stockholders of $7.7 million, or $0.16 per share, basic and diluted, for the same period in 2007. For the year ended December 31, 2008, Antigenics incurred a net loss attributable to common stockholders of $29.5 million, or $0.47 per share, basic and diluted, compared with a net loss attributable to common stockholders of $37.6 million, or $0.81 per share, basic and diluted, for the year ended December 31, 2007.
